Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Cancer Recurrence, Clinical Trials, High Risk Prostate Cancer, Intermediate Risk Prostate Cancer, Low Risk Prostate Cancer, Metastatic Castration Resistant Prostate Cancer (MCRPC), Metastatic Castration Sensitive Prostate Cancer (MCSPC), Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT04550494
Phase: Phase 2
Trial Summary: This phase II trial studies if talazoparib works in patients with cancer that has spread to other places in the body (advanced) and has mutation(s) in deoxyribonucleic acid (DNA) d – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)
Acronym:

Pin It on Pinterest